Cleveland Clinic

Questions discussed in this category

How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?

0 Answers available

How do you sequence therapy in an older patient with newly-diagnosed blastoid mantle cell lymphoma with a 17p deletion?

1 Answer available

How would you manage an asymptomatic elderly frail patient with newly diagnosed mantle cell lymphoma with TP53 mutation?

Ki67 = 90% with multiple small nodes on PET scan and normal CBC

1 Answer available

How would you treat stage II pediatric type follicular lymphoma that is not amenable to surgical resection in an adolescent and young adult patient?

1 Answer available

What treatment regimen would you recommend for young adults with platinum refractory relapsed germ cell tumors?

2 Answers available

Papers discussed in this category

Ann Oncol, 2007 Nov 15

Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.

Zhonghua Bing Li Xue Za Zhi,

[Clinicopathological characteristics of pediatric-type follicular lymphomas: an analysis of 37 cases].

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

Outcome of deferred initial therapy in mantle-cell lymphoma.

The New England journal of medicine, 2015-11-05

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

Haematologica, 2018 May 24

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma.

Blood,

p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.

Leukemia, 2011 Jul 01

Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.

Haematologica, 2019 Sep 19

mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.

Blood, 2017 Aug 17

mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.

Blood, 2015 May 28

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.

British journal of haematology, 2017-11

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.

J Clin Oncol, 2016 Feb 29

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.

Lancet Haematol, 2016 Dec 05

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

Lancet Oncol, 2022 Jan 21

Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.

N Engl J Med,

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Related Topics